ZURICH (Reuters) - Swiss pharma group Roche said it would discontinue a late-stage study of investigational anti-amyloid medicine in pre-dementia Alzheimer's disease, following a pre-planned futility analysis and recommendation by the independent Data Monitoring Committee. The company also said a late-stage study in people with previously untreated advanced HER2-positive breast cancer showed three of its treatments helped people live without their disease worsening, meeting its non-inferiority endpoint. ...
via Health News Headlines - Yahoo News http://ift.tt/1wRXdJm
No comments:
Post a Comment